The triglyceride-glucose index as a clinical useful marker for metabolic associated fatty liver disease (MAFLD): a population-based study among Iranian adults.
Metabolic associated fatty liver disease
Non-alcoholic fatty liver disease
Predictive value
Triglyceride-glucose index
Journal
Journal of diabetes and metabolic disorders
ISSN: 2251-6581
Titre abrégé: J Diabetes Metab Disord
Pays: Switzerland
ID NLM: 101590741
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
12
09
2021
accepted:
17
11
2021
entrez:
8
6
2022
pubmed:
9
6
2022
medline:
9
6
2022
Statut:
epublish
Résumé
There is a bi-directional association between non-alcoholic fatty liver disease (NAFLD) and insulin resistance in type 2 diabetes mellitus (T2DM) and metabolic syndrome. The triglyceride-glucose (TyG) index is a novel surrogate marker of insulin resistance. In this population-based study, we aimed firstly to investigate the association of the TyG-index with metabolic-associated fatty liver disease (MAFLD) risk. This case-control study used the data from the first phase of the Persian Cohort Study in Sabzevar. Of 4,241 participants aged 35 to 70 years, we identified and recruited 968 MAFLD cases and 964 age- and sex-adjusted controls. Demographic, lifestyle, anthropometric, and biochemical information were collected. We calculated TyG and a new index combined of TyG and alanine aminotransferase (TyG-ALT). We used the multivariable unconditional logistic regression model to calculate the odds ratios (ORs) of the TyG and TyG-ALT for having MAFLD. Among those in the highest relative to the lowest TyG and TyG-ALT tertiles, the multivariable-adjusted ORs were 12.01 (95% CI [confidence interval] 9.03 - 15.98; The higher TyG and TyG-ALT scores were significantly positively associated with higher MAFLD risk in the Iranian population.
Sections du résumé
Background and aims
UNASSIGNED
There is a bi-directional association between non-alcoholic fatty liver disease (NAFLD) and insulin resistance in type 2 diabetes mellitus (T2DM) and metabolic syndrome. The triglyceride-glucose (TyG) index is a novel surrogate marker of insulin resistance. In this population-based study, we aimed firstly to investigate the association of the TyG-index with metabolic-associated fatty liver disease (MAFLD) risk.
Methods
UNASSIGNED
This case-control study used the data from the first phase of the Persian Cohort Study in Sabzevar. Of 4,241 participants aged 35 to 70 years, we identified and recruited 968 MAFLD cases and 964 age- and sex-adjusted controls. Demographic, lifestyle, anthropometric, and biochemical information were collected. We calculated TyG and a new index combined of TyG and alanine aminotransferase (TyG-ALT). We used the multivariable unconditional logistic regression model to calculate the odds ratios (ORs) of the TyG and TyG-ALT for having MAFLD.
Results
UNASSIGNED
Among those in the highest relative to the lowest TyG and TyG-ALT tertiles, the multivariable-adjusted ORs were 12.01 (95% CI [confidence interval] 9.03 - 15.98;
Conclusions
UNASSIGNED
The higher TyG and TyG-ALT scores were significantly positively associated with higher MAFLD risk in the Iranian population.
Identifiants
pubmed: 35673435
doi: 10.1007/s40200-021-00941-w
pii: 941
pmc: PMC9167320
doi:
Types de publication
Journal Article
Langues
eng
Pagination
97-107Informations de copyright
© Springer Nature Switzerland AG 2021.
Déclaration de conflit d'intérêts
Competing interestsThe authors declare no competing interests.
Références
Lipids Health Dis. 2017 Oct 16;16(1):203
pubmed: 29037210
Clin Sci (Lond). 2017 Nov 6;131(22):2701-2704
pubmed: 29109303
Cardiovasc Diabetol. 2014 Oct 20;13:146
pubmed: 25326814
Lipids Health Dis. 2017 Sep 13;16(1):175
pubmed: 28903774
Trends Endocrinol Metab. 2019 Oct;30(10):701-709
pubmed: 31422872
Prim Care Diabetes. 2020 Apr;14(2):161-167
pubmed: 31466834
Diabetes Care. 2019 Aug;42(8):1569-1573
pubmed: 31182490
Can J Gastroenterol Hepatol. 2019 Oct 7;2019:5121574
pubmed: 31687367
Lipids Health Dis. 2017 Jan 19;16(1):15
pubmed: 28103934
Lipids Health Dis. 2020 Oct 7;19(1):218
pubmed: 33028338
Lipids Health Dis. 2020 Oct 15;19(1):226
pubmed: 33059672
J Transl Med. 2016 Sep 07;14:260
pubmed: 27604550
Adv Exp Med Biol. 2017;960:277-304
pubmed: 28585204
Metab Syndr Relat Disord. 2021 Apr;19(3):167-173
pubmed: 33259744
Endocr Rev. 2019 Oct 1;40(5):1367-1393
pubmed: 31098621
Lipids Health Dis. 2020 Nov 8;19(1):235
pubmed: 33161896
Endocrine. 2021 Apr;72(1):124-131
pubmed: 33433893
PLoS One. 2019 Mar 7;14(3):e0212963
pubmed: 30845237
Hepatology. 2016 Jul;64(1):73-84
pubmed: 26707365
Metab Syndr Relat Disord. 2008 Dec;6(4):299-304
pubmed: 19067533
Front Neurol. 2020 Jun 10;11:456
pubmed: 32587566
Expert Rev Gastroenterol Hepatol. 2020 Nov;14(11):1035-1046
pubmed: 32715793
Lipids Health Dis. 2018 Nov 20;17(1):262
pubmed: 30458848
Endocrinol Metab (Seoul). 2019 Jun;34(2):179-186
pubmed: 31257745
Am J Epidemiol. 2018 Apr 1;187(4):647-655
pubmed: 29145581
J Hepatol. 2020 Jul;73(1):202-209
pubmed: 32278004
Cardiovasc Diabetol. 2017 Aug 23;16(1):108
pubmed: 28830471
Hepatology. 2021 Mar;73(3):1194-1198
pubmed: 32544255
Ann Hepatol. 2016 Sep-Oct;15(5):715-20
pubmed: 27493110
J Intern Med. 2018 Apr;283(4):356-370
pubmed: 29280273
J Hepatol. 2017 Oct;67(4):829-846
pubmed: 28545937
Aliment Pharmacol Ther. 2003 Apr;17(8):977-86
pubmed: 12694079
J Gastroenterol Hepatol. 2013 Dec;28 Suppl 4:64-70
pubmed: 24251707
J Endocrinol Invest. 2020 Jul;43(7):995-1000
pubmed: 31970690
Cardiovasc Diabetol. 2019 Jul 25;18(1):95
pubmed: 31345238
Gastroenterology. 2012 Jun;142(7):1592-609
pubmed: 22656328
Aliment Pharmacol Ther. 2011 Aug;34(3):274-85
pubmed: 21623852
BMC Gastroenterol. 2006 Nov 02;6:33
pubmed: 17081293
Health Policy Plan. 2006 Nov;21(6):459-68
pubmed: 17030551
Pediatr Diabetes. 2016 Sep;17(6):458-65
pubmed: 26251318
Cells. 2020 Apr 17;9(4):
pubmed: 32316690
Cardiovasc Diabetol. 2020 Jul 8;19(1):108
pubmed: 32641127